Traws Pharma Completes Phase 2 Enrollment for COVID Candidate

An announcement from Traws Pharma ( (TRAW) ) is now available.

On January 26, 2026, Traws Pharma reported it had completed enrollment in a 90-patient open-label Phase 2 study of its oral COVID-19 candidate ratutrelvir, comparing it with PAXLOVID in PAXLOVID-eligible patients and in a separate cohort of patients ineligible for ritonavir-based regimens, a group often at higher risk of severe disease. Interim clinical observations highlighted fewer adverse events, absence of viral rebound to date, faster and sustained symptom resolution, and favorable tolerability for ratutrelvir, reinforcing its potential to address a sizeable market segment that cannot use ritonavir and to offer a differentiated profile that may also have implications for reducing post-acute sequelae of SARS-CoV-2 infection. The company also advanced its influenza franchise, outlining plans to pursue an additional indication for tivoxavir marboxil as a once-monthly oral prophylactic for seasonal influenza, supported by earlier Phase 1 data showing prolonged therapeutic blood levels and a new compressed tablet formulation expected to provide 28 days of protection, with a human influenza prophylaxis challenge study already scheduled for June 2026, positioning Traws for multiple upcoming clinical and value inflection points in the multi-billion-dollar antiviral market for COVID-19 and flu.

The most recent analyst rating on (TRAW) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Spark’s Take on TRAW Stock

According to Spark, TipRanks’ AI Analyst, TRAW is a Neutral.

The score is held back primarily by weak financial performance (minimal revenue, widening losses, negative equity, and increasing cash burn). Offsetting factors include constructive recent pipeline/regulatory progress and a bullish-but-extended technical setup; valuation signals are hard to rely on given the lack of meaningful earnings.

To see Spark’s full report on TRAW stock, click here.

More about Traws Pharma

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral small-molecule antivirals targeting critical respiratory viral threats, including COVID-19/Long COVID, bird flu and seasonal influenza. Its lead pipeline candidates include ratutrelvir, a ritonavir-independent Mpro/3CL protease inhibitor for COVID-19, and tivoxavir marboxil, a cap-dependent endonuclease inhibitor being developed as a single-dose treatment for bird flu and seasonal influenza, as well as for prophylactic use; the company is also seeking partners for legacy oncology assets rigosertib and narazaciclib.

Average Trading Volume: 440,132

Technical Sentiment Signal: Sell

Current Market Cap: $19.34M

For a thorough assessment of TRAW stock, go to TipRanks’ Stock Analysis page.